000			01480 a2200457 4500
005			20250513222824.0
264		0	_c20001120
008			200011s 0 0 eng d
022			_a0008-543X
040			_aNLM _beng _cNLM
100	1		_aHeinzerling, L M
245	0	0	_aReduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. _h[electronic resource]
260			_bCancer _cOct 2000
300			_a1835-44 p. _bdigital
500			_aPublication Type: Case Reports; Clinical Trial; Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Murine-Derived
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInfusions, Intravenous
650	0	4	_aLymphoma, B-Cell _xdrug therapy
650	0	4	_aLymphoma, Large B-Cell, Diffuse _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aRituximab
650	0	4	_aSkin Neoplasms _xdrug therapy
650	0	4	_aTreatment Outcome
700	1		_aUrbanek, M
700	1		_aFunk, J O
700	1		_aPeker, S
700	1		_aBleck, O
700	1		_aNeuber, K
700	1		_aBurg, G
700	1		_avon Den Driesch, P
700	1		_aDummer, R
773	0		_tCancer _gvol. 89 _gno. 8 _gp. 1835-44
999			_c10987576 _d10987576